Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEN Compugen	$1.45 +1.4%	$1.40	$1.13 ▼ $2.66	$129.39M	2.61	367,848 shs	198,521 shs
FDMT 4D Molecular Therapeutics	$3.47 +1.5%	$3.23	$2.24 ▼ $28.93	$160.75M	2.87	833,467 shs	291,686 shs
KOD Kodiak Sciences	$3.50 -2.2%	$3.31	$1.92 ▼ $11.60	$184.67M	2.42	347,208 shs	173,413 shs
PSTI Pluristem Therapeutics		$1.24	$0.95 ▼ $3.45	$32.35M	1.91	715,259 shs	2,128 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEN Compugen	+1.40%	+4.32%	+0.69%	-21.62%	-42.46%
FDMT 4D Molecular Therapeutics	+1.46%	-2.25%	+3.89%	-22.54%	-86.06%
KOD Kodiak Sciences	-2.23%	-1.13%	-16.86%	-12.72%	+16.67%
PSTI Pluristem Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGEN Compugen	2.2449 of 5 stars	3.5	4.0	0.0	0.0	3.4	0.0	0.0
FDMT 4D Molecular Therapeutics	3.23 of 5 stars	4.3	3.0	0.0	0.0	2.7	1.7	0.6
KOD Kodiak Sciences	4.0902 of 5 stars	3.0	3.0	0.0	4.6	1.8	3.3	0.6
PSTI Pluristem Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEN Compugen	3.00	Buy	$4.00	175.86% Upside
FDMT 4D Molecular Therapeutics	2.60	Moderate Buy	$29.56	751.75% Upside
KOD Kodiak Sciences	2.00	Hold	$9.00	157.14% Upside
PSTI Pluristem Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PSTI, FDMT, CGEN, and KOD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/10/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/9/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $25.00
5/9/2025	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $44.00
5/9/2025	FDMT 4D Molecular Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $38.00
4/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
4/8/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
3/31/2025	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.00 ➝ $3.00
3/22/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
3/10/2025	FDMT 4D Molecular Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $40.00
3/7/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEN Compugen	$27.59M	4.69	N/A	N/A	$0.73 per share	1.99
FDMT 4D Molecular Therapeutics	$23K	6,989.03	N/A	N/A	$7.20 per share	0.48
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$5.07 per share	N/A
PSTI Pluristem Therapeutics	$20K	0.00	N/A	N/A	$1.80 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEN Compugen	-$18.75M	-$0.16	72.50	N/A	N/A	2.67%	2.62%	1.36%	8/5/2025 (Estimated)
FDMT 4D Molecular Therapeutics	-$100.84M	-$3.18	N/A	N/A	N/A	N/A	-28.00%	-26.16%	8/14/2025 (Estimated)
KOD Kodiak Sciences	-$260.49M	-$3.63	N/A	N/A	N/A	N/A	-84.52%	-45.40%	8/13/2025 (Estimated)
PSTI Pluristem Therapeutics	-$49.87M	-$1.47	N/A	N/A	N/A	N/A	-100.63%	-55.46%	N/A

Latest PSTI, FDMT, CGEN, and KOD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/19/2025	Q1 2025	CGEN Compugen	-$0.06	-$0.08	-$0.02	-$0.08	$3.70 million	$2.28 million
5/14/2025	Q1 2025	KOD Kodiak Sciences	-$0.89	-$1.09	-$0.20	-$1.09	N/A	N/A
5/8/2025	Q1 2025	FDMT 4D Molecular Therapeutics	-$0.84	-$0.86	-$0.02	-$0.86	$0.53 million	N/A
3/27/2025	Q4 2024	KOD Kodiak Sciences	-$0.90	-$0.84	+$0.06	-$0.84	N/A	N/A
3/4/2025	Q4 2024	CGEN Compugen	$0.07	-$0.07	-$0.14	-$0.07	$17.47 million	$1.47 million
2/28/2025	Q4 2024	FDMT 4D Molecular Therapeutics	-$0.80	-$0.90	-$0.10	-$0.90	$2.28 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
PSTI Pluristem Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEN Compugen	N/A	4.14	4.14
FDMT 4D Molecular Therapeutics	N/A	17.33	17.33
KOD Kodiak Sciences	N/A	8.42	8.42
PSTI Pluristem Therapeutics	0.57	8.22	8.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEN Compugen	12.22%
FDMT 4D Molecular Therapeutics	99.27%
KOD Kodiak Sciences	89.06%
PSTI Pluristem Therapeutics	16.94%

Insider Ownership

Company	Insider Ownership
CGEN Compugen	9.50%
FDMT 4D Molecular Therapeutics	9.60%
KOD Kodiak Sciences	45.30%
PSTI Pluristem Therapeutics	5.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEN Compugen	70	89.24 million	80.76 million	Optionable
FDMT 4D Molecular Therapeutics	120	46.33 million	42.85 million	Optionable
KOD Kodiak Sciences	90	52.76 million	28.79 million	Optionable
PSTI Pluristem Therapeutics	153	32.35 million	30.60 million	Optionable

PSTI, FDMT, CGEN, and KOD Headlines

Recent News About These Companies

Editorial Board — Medscape Oncology

September 2, 2024 | medscape.com

NBRVF Nabriva Therapeutics plc

August 18, 2023 | seekingalpha.com

Pluri CEO Issues Shareholder Update

July 25, 2022 | finance.yahoo.com

Pluristem Therapeutics Inc. Changes its Name to "Pluri Inc." Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries

July 25, 2022 | benzinga.com

Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries

July 25, 2022 | finance.yahoo.com

Pluristem (PSTI) Phase III Study Misses Goal, Stock Down

July 14, 2022 | finance.yahoo.com

Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery

July 13, 2022 | finance.yahoo.com

Pluristem's Phase 3 Study Of PLX-PAD To Treat Muscle Injury Does Not Meet Primary Goal

July 13, 2022 | markets.businessinsider.com

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

July 13, 2022 | finance.yahoo.com

Pluristem: Fiscal Q3 Earnings Snapshot

May 10, 2022 | apnews.com

Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership

March 28, 2022 | finance.yahoo.com

Pluristem PLX-R18 shows promise in blood cell recovery in cell transplant patients in trial

March 23, 2022 | seekingalpha.com

Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions

March 23, 2022 | finance.yahoo.com

Pluristem Therapeutics, Inc. Common Stock (PSTI)

March 21, 2022 | nasdaq.com

Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture

March 8, 2022 | finance.yahoo.com

Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform

February 24, 2022 | finance.yahoo.com

Pluristem: Fiscal Q2 Earnings Snapshot

February 8, 2022 | timesunion.com

What Are The Analysts’ Predictions For Pluristem Therapeutics Inc. (NASDAQ: PSTI)?

January 18, 2022 | stocksregister.com

Thinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?

January 12, 2022 | marketwatch.com

Pluristem Therapeutics Inc. (NASDAQ: PSTI) Is On The Rise

January 11, 2022 | stocksregister.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSTI, FDMT, CGEN, and KOD Company Descriptions

Compugen NASDAQ:CGEN

$1.45 +0.02 (+1.40%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$1.46 +0.01 (+0.34%)

As of 05/28/2025 07:10 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

4D Molecular Therapeutics NASDAQ:FDMT

$3.47 +0.05 (+1.46%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$3.48 +0.00 (+0.14%)

As of 05/28/2025 07:52 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Kodiak Sciences NASDAQ:KOD

$3.50 -0.08 (-2.23%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$3.72 +0.22 (+6.40%)

As of 05/28/2025 04:34 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Pluristem Therapeutics NASDAQ:PSTI

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time